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a b s t r a c t
In order to adapt to the reduced availability of nutrients and oxygen in the tumor microenvironment and
the increased requirements of energy and building blocks necessary for maintaining their high prolif-
eration rate, malignant cells undergo metabolic changes that result in an increased production of lactate,
nitric oxide, reactive oxygen species, prostaglandins and other byproducts of arachidonic acid meta-
bolism that inﬂuence both the composition of the inﬂammatory microenvironment and the function of
the tumor-associated macrophages (TAMs). In response to cues present in the TME, among which
products of altered tumor cell metabolism, TAMs are also required to reprogram their metabolism, with
activation of glycolysis, fatty acid synthesis and altered nitrogen cycle metabolism. These changes result
in functional reprogramming of TAMs which includes changes in the production of cytokines and
angiogenetic factors, and contribute to the tumor progression and metastasis. Understanding the
metabolic changes governing the intricate relationship between the tumor cells and the TAMs represents
an essential step towards developing novel therapeutic approaches targeting the metabolic reprog-
ramming of the immune cells to potentiate their tumoricidal potential and to circumvent therapy
resistance.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Tumor microenvironment (TME) consists of a complex mixture
of malignantly transformed cells, immune cells, and stromal cells
which fulﬁll different functions. Some of these cells, including the
dendritic cells (DC), CD8þ and CD4þ T-lymphocytes, natural killer
(NK) cells, are activated in order to contain the tumor and prevent
immune evasion and progression of the disease. Other immune
cells such as tolerogenic DC's, regulatory T-cells (Treg), myeloid
derived suppressor cells (MDSC), tumor-associated neutrophils and
tumor associated macrophages (TAM), on the other hand, promote
tumor growth, progression, invasion, angiogenesis and suppress
the antitumoral immune responses [1].
During the last decades, it has become clear that inmany tumors
a proinﬂammatory TME promotes cancer development, progres-
sion and metastasis [2e5]. Moreover, the composition of the
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inﬂammatory TME correlates with the clinical outcome. In many
types of cancer a TME enriched in T-lymphocytes has been asso-
ciated with a more favorable prognosis, whereas an abundant
inﬁltration with TAMs has been associated with a poor outcome
[6e11]. TAMs are one of the most prominent components in the
TME. They are characterized by a high functional plasticity [12,13].
Once monocytes are recruited at the tumor site, they undergo
reprogramming into TAMs, leading to gain of protumoral functions
such as supporting the tumor growth, promoting angiogenesis,
tumor invasion and metastases and suppressing T-cells that are
responsible for the antitumoral responses. The functional reprog-
ramming of the TAMs is a complex process that has not yet been
elucidated. However, emerging evidence suggest that both the tu-
mor cells and the TAMs undergo changes in their cellular meta-
bolism that shapes their functional phenotype in a mutual fashion,
with the nature of this relationship orchestrating the complex
process of tumor progression. This review focuses on the metabolic
changes that are responsible for the cross-talk between the tumor
cells and the TAM.
Tumor cell metabolism shapes the inﬂammatory TME
During the tumor development, the TME changes continuously
in parallel with the growth of the tumor. These changes shape on
the one hand its cellular content through the release of various
recruitment factors resulting in accumulation of speciﬁc types of
immune cells into the TME, and on the other hand inﬂuence the
function of these immune cells and the complex relationship be-
tween these cells and the tumor cells [14e16]. The TME is typically
characterized by hypoxia and a lack of blood bourn nutrients, while
being enriched in protons, reactive nitrogen species (RNS) and
other byproducts released from the activated tumor cell
metabolism.
Tumor cells need to adapt their metabolism in order to survive
in this unfavorable, nutrients- and oxygen-deprived TME, and to
respond to the increased energy demands required by their high
proliferation rate (Fig. 1) [2]. These metabolic changes have been
observed and described almost one century ago by Otto Warburg
and are now referred to as the “Warburg effect” [17]. In conditions
characterized by sufﬁcient availability of oxygen and nutrients,
particularly glucose, normal cells burn glucose by using the
oxidative phosphorylation (OXPHOS) that takes place in the mito-
chondria as the main source of energy [18,19]. In hypoxic condi-
tions, the cellular metabolism shifts towards anaerobic glycolysis to
produce energy, a process that is far less efﬁcient in terms of
adenosine triphosphate (ATP) production than OXPHOS. Warburg
effect refers to the phenomenon through which cancer cells shift
their energy metabolism towards glycolysis, even in normoxic
conditions. In this process, which takes place in the cytosol, cells
use the glucose to form pyruvate and ATP. Though this pathway
seems relatively inefﬁcient in terms of energy metabolism, result-
ing in generation of only 2 molecules of ATP per each molecule of
glucose, as compared to 36 molecules of ATP per molecule of
glucose generated through OXPHOS, it also results in generation of
nicotinamide adenine dinucleotide (NAD) in its reduced form
NADH. NADH is a key cofactor used by several enzymes that direct
intermediate products to biosynthetic pathways and enable
anabolic growth. The tumor cell metabolism is therefore charac-
terized by an increased glucose consumption, reﬂected by the up-
regulation of the glucose transporter (GLUT1) at the surface of
the tumor cells, their increased glucose uptake and oxygen con-
sumption [20,21].
The capacity of tumor cells to mount glucose metabolism has
also been used for diagnostic purposes, as it represents the physi-
ologic principle of the functional ﬂuorodeoxyglucose - positron
emission tomography imaging technique. As a result of the
increased glycolysis, the pyruvate is reduced to lactate. This results
in production of high amounts of lactate that are released in the
TME and cause local acidiﬁcation, while the pH within the cancer
cells remains normal. The latter may be explained by the up-
regulation of lactate and protons efﬂux channels in these cells. In
several tumor types, besides evidence of increased glycolysis and
expression of GLUT1 in the tumor cells, an increased expression of
different proteins such asmonocaroxylic acid transporter 1 (MCT1),
monocaroxylic acid transporter 4 (MCT4), carbonic anhydrase IX
(CAIX) involved in the lactate and Hþ trafﬁcking has been found
[22]. The signiﬁcant reduction of the pH in the TME result in a
cytotoxic environment for cells, including the immune cells that are
recruited and activated to eliminate the tumor and to limit its
progression, that are not equipped to survive in these conditions.
This confers a survival advantage to the cancer cells while limiting
the number and the functional capacity of the immune cells to elicit
antitumoral responses and thus inﬂuencing the spatial structure of
the TME [15]. In addition to that, waste products of the tumor
metabolism such as lactic acid have been shown to shape the
functional phenotype of the immune cells towards more tolero-
genic phenotypes and conferring them with protumorigenic and
proangiogenic properties [23,24]. In a murine model of Lewis lung
carcinoma, Colegio et al. showed that, in normoxic conditions,
lactate induced an increased expression of Vegf and Arg1 and dif-
ferentiation of TAMs into a protumoral phenotype [23]. This effect
was mediated through stabilization of HIF1alpha transcription
factor, similarly to the induction of vascular endothelial growth
factor (VEGF) in hypoxic conditions, a process that has been asso-
ciated with increased angiogenesis and expansion of the MDSC
population in malignant tumors [25,26].
Changes in tumor cell metabolism are not limited to the glucose
metabolism. Through its different intermediate metabolites,
glycolysis is directly interconnected with other intracellular
metabolic pathways. This includes the pentose phosphate pathway
Fig. 1. Changes in tumor cell metabolism that shape the inﬂammatory tumor
microenvironment. In order to respond to the reduced availability of nutrients and
oxygen which typically characterize the tumor microenvironment and to match the
requirements of energy and building blocks necessary for maintaining a high prolif-
eration rate, malignant cells undergo metabolic changes including increased uptake of
glucose through upregulation of glucose transporters (GLUT1), activation of glycolysis
which results in increased production of lactate, increased fatty acids (FA) uptake and
synthesis and increased uptake of glutamine to fuel the TCA cycle. This process results
in increased production of lactate, NO, ROS, RNS and prostaglandins and other
byproducts of arachidonic acid metabolism that inﬂuence the spatial architecture of
the inﬂammatory microenvironment and the function of the tumor-associated
macrophages.
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(PPP) through the intermediate glucose-6-phosphate, the amino
acid metabolism by the intermediate 3-phosphoglycerate, and to
the fatty acid (FA) metabolism by pyruvate into the tricarboxylic
acid (TCA) cycle [27].
Pyruvate is converted into acetyl coenzyme A (acetyl CoA)
which is directed into the mitochondrion where it enters the TCA
cycle to generate the NADH and ﬂavin adenine dinucleotide
(FADH2) which donate electrons to the electron transport chain in
the mitochondrial OXPHOS to generate ATP that is highly required
by the proliferating cells [28]. Interestingly, when pyruvate avail-
ability becomes limited, the cell can use other metabolites to fuel
the TCA cycle. As such, FAs can be converted into acetyl CoA to enter
the TCA cycle by forming citrate and glutamate that is converted
into a-ketoglutarate. Upon increased nutrient diversion to the TCA
cycle, intermediates of the TCA such as citrate can also be used for
production of lipids and amino acids [27,29].
Through glucose-6-phosphate glycolysis is linked to the PPP
that takes place in the cytosol and leads to production of nucleotide
and amino acid precursors as well as nicotinamide adenine dinu-
cleotide phosphate (NADPH), which is necessary for the production
of reactive oxygen species (ROS) and nitric oxide (NO) and for FA
synthesis [27,30].
In addition to glucose and glutamine, cancer cells can use FAs as
an important source of energy. The b-oxidation of the FAs in the
mitochondrion generates large amounts of acetyl CoA, NADH and
FADH2, electron carriers that can be further used to generate high
amounts of ATP in the TCA cycle [27,31]. Changes in lipid meta-
bolism have been increasingly recognized as important ways of
communication between the cancer cells and the surrounding
stromal and immune cells [32]. On the one hand, cancer cells thrive
on rich sources of free FAs such as adipose tissue, as reﬂected by the
FA exchange between metastases of ovarian carcinoma in omental
adipose tissue and between adipocytes and metastatic prostate
cancer cells [33,34]. On the other hand, the FAs can be used by the
cancer cells to produce other bioactive lipids and mediators that in
term, can inﬂuence the function of other cells in a paracrine fashion
[32].
Malignant tumors have been associated with an increased
metabolism of arachidonic acid, a precursor for eicosanoids such as
leukotrienes, prostaglandins, thromboxane hydroxiepoxyeicosate-
traenoic acid (HETE), FAs, as well as other cyclooxygenases (COX)
and lipoxygenases (LO) products. Eicosanoids are expressed in
higher levels in malignant tumors and can be produced by cancer
cells, but also by stromal cells and immune cells including myeloid-
derived cells in the TME and therefore are likely involved in the
cross-talk between these cells [35]. Through binding to their re-
ceptors which include peroxisome proliferator-activated receptors
(PPARs), sterol regulatory element binding protein 1 (SREBP1), Toll
like receptor 4 (TLR4), and G protein-coupled receptors eicosanoids
can inﬂuence the functions of immune cells to induce immuno-
suppression. In this respect, prostaglandin E2 (PGE2), which has
been detected at high levels in cancers associated with inﬂamma-
tion, has been shown to promote differentiation of monocytes into
TAMs with immunosuppressive phenotype in cervical cancer and
to induce activation of MDSCs in breast cancer [36e38]. Further-
more, LO isoform 5-LO could be involved in recruitment and
expansion of immune cell populations within the tumors [39,40].
In a recent study, we compared the transcriptome of thyroid
cancer-induced macrophages with the transcriptome of 29
different macrophage transcription proﬁles (see Xue et al. [41]). We
found that the transcriptome of the thyroid cancer-induced mac-
rophages after 4-h of co-culture were characterized by gene mod-
ules similar to those found in macrophages stimulated by FAs
(linoleic, oleic, lauric acid), lipopolysaccharide (LPS), or a combi-
nation of tumor necrosis factor (TNF), PGE and Pam2Cys whereas
the transcriptome of thyroid cancer-induced macrophages after
24 h co-culture resembled the gene modules found after inter-
leukin 4 (IL-4) stimulation in combinationwith inﬂammatory genes
stimulated by palmitic acid [24,41]. In line with this, Schumann
et al. found that TAMs isolated from ovarian carcinoma patients
showed an up-regulation of the vast majority of direct PPARb/
d target genes in the TAMs compared to the monocyte-derived
macrophages and suggest that this may reﬂect a pro-tumorigenic
polarization of the TAMs [42]. Lipidomic analysis of the TAMs
revealed that this up-regulation of PPARb/d target genes was due to
high concentrations in the tumor ascites of polyunsaturated FA,
especially linoleic acid and arachidonic acid, which accumulate in
highly stable lipid droplets in TAMs and provide a source of PPARb/
d ligands to TAMs, contributing to a stable up-regulation of PPARb/
d target genes. These genes include pyruvate dehydrogenase kinase
4 (PDK4), which, interestingly, shifts glucose catabolism towards
aerobic glycolysis, rendering TAMs less dependent on oxygen and
thereby enabling them to cope with hypoxic conditions in the TME
[43].
Taken together, these ﬁndings highlight the important role of
tumor metabolic reprogramming and tumor-related metabolites in
deﬁning the inﬂammatory TME, which in term promotes the tumor
progression.
Metabolic reprogramming of TAMs shapes their functional
phenotype
TAMs are one of themost abundant components of TME, and are
involved in multiple processes leading to local growth and pro-
gression of the primary tumor and promotion of metastasis. Once
monocytes are recruited to the TME, these immune cells need to
undergo metabolic adaptations in order to survive in the harsh
tumor milieu (Fig. 2). These metabolic adaptations result in sig-
niﬁcant changes in the functional phenotypes of the TAMs. In
previous literature, TAMs functional phenotype has often been
deﬁned either as M1-like TAMs (similar to the interferon-g (IFN-g),
TNFea or TLR4 activation status, also known as “activated”) or as
M2-like TAMs (similar to the IL-4 and IL-13 activation status, also
known as “alternatively activated”). M1-like TAMs have classically
been regarded as tumor suppressors and M2-like TAMs as tumor
promoters [44]. More recently, it has become clear however that
such a dichotomous model does not accurately reﬂect the large
variety of functional phenotypes of activated macrophages. Large-
scale transcriptomic studies have shown that there is a broad
heterogeneity of macrophage populations, depending on the cues
that they are exposed to [41]. Moreover, tumors may contain
distinct subpopulations of TAMs in different tumor regions, dis-
playing either a more M1-like or M2-like phenotype [45,46]. To
deﬁne their activation status, it has recently proposed to use a
nomenclature based on the source of macrophages, the activators,
and markers to describe macrophage activation [47]. However,
because most of the previous literature used the M1/M2 nomen-
clature and the metabolic proﬁle of non-M1/M2 is largely unex-
plored, we will use the M1/M2 nomenclature henceforth in this
review, but we will mention also the source, the activators, and the
markers of the macrophages used in different studies if this infor-
mation is available.
In general, the metabolic proﬁle of LPS/IFN-g -activated mac-
rophages is characterized by an enhanced glycolysis, PPP and FA
synthesis, and a truncated TCA cycle leading to an accumulation of
succinate and citrate. In contrast, the metabolism of IL-4/IL-13-
activated macrophages is characterized by OXPHOS, a decreased
glycolysis and PPP, and FA oxidation (FAO) [48]. Furthermore, IL-4/
IL-13-activated macrophages in murine models upregulate argi-
nase 1 [49e51]. Nevertheless, little is known on the metabolic
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reprogramming of the TAMs and its role in modulating the func-
tional phenotype of these cells in the context of cancer develop-
ment and progression.
Glucose metabolism of the TAMs
Recent literature suggests that, in the TME, TAMs are forced to
compete with cancer cells for nutrients, particularly glucose and
therefore undergo changes in their glucose metabolism, in a similar
fashion as the tumor cells do. Several studies indicate that TAMs
have an activated aerobic glycolysis, which also contributes to their
functional reprogramming.
Comparing the proteome of bonemarrow-derivedmacrophages
stimulated with tumor extract with the naive bone marrow-
derived macrophages, Liu et al. have shown that tumor extract-
stimulated bone marrow-derived macrophages depict a molecu-
lar signature characterized by up-regulated glycolysis. Further-
more, stimulation of these cells and of primary TAMs from MMTV-
PyMTmicewith tumor extract solution from a breast cancer patient
showed increased expression of hexokinase-2 (HK2), which is a key
glycolytic enzyme, and its downstream products PDKL and ENO1
[52]. Accordingly, using a two-wells co-culture model of thyroid
cancer cell lines and monocytes from healthy volunteers, we have
found that macrophages that were obtained either by co-culture
with thyroid cancer cells or those that were stimulated with thy-
roid carcinoma-conditionedmedium displayed a distinct metabolic
transcriptomic signature with increased glycolysis and activation of
protein kinase B/mammalian target of rapamycin (AKT1/mTOR)
pathway, an essential regulator of cell metabolism. These thyroid
cancer-induced macrophages also had a pro-inﬂammatory
phenotype which could be partially abrogated by blocking the
lactate receptor, conﬁrming the paracrine effects of tumor-derived
lactate in modulating the function of TAMs as described by Colegio
et al. Immunohistochemistry analysis also showed increased
expression of glycolytic enzymes and lactate receptor in TAMs from
thyroid cancer tissue samples. Interestingly, in this study, the pro-
inﬂammatory phenotype of the thyroid cancer-induced macro-
phages was associated with epigenetic changes that could be
abrogated by treatment with an mTOR inhibitor, linking the im-
mune cell metabolism with its functional capacity to produce pro-
inﬂammatory cytokines [24].
Changes in TAMs cell metabolism have also been linked to
promotion of invasion and metastasis [53,54]. Penny et al. showed
that tumor-conditioned medium differentiated from human pe-
ripheral blood monocytes co-cultured with pancreatic ductal
adenocarcinoma (PDCA) cell lines displayed a pro-metastatic
phenotype, promoted vascular network formation, increased
extravasation of tumor cells out of blood vessels and induced
higher level of epithelial-to-mesenchymal (ETM) transition as
compared to macrophages differentiated through co-culture with
normal pancreatic cells. The PDCA-induced macrophages also
showed an increased glycolysis; inhibition of glycolysis using a HK2
competitive inhibitor 2-deoxiglucose (2DG) abrogated the func-
tional phenotype of these cells [53]. Interestingly, it has been
shown that 2DG inhibits the IL-1b production by LPS-stimulated
macrophages, but not the production of TNF-a or IL-6, by
decreasing the succinate level in the macrophages [55]. Further-
more, in several in vitro and in vivo studies, 2DG suppressed the
viability, proliferation and motility of cancer cells when combined
with other targeted therapy, and it is being used in clinical trials for
cancer treatment [56e64].
It has been previously shown that TAMs can promote angio-
genesis and metastasis. However, it has only recently been shown
that changes in the TAMs cell metabolism play an important role in
the functional reprogramming towards a proangiogenic, pro-
metastatic phenotype. In solid tumors, hypoxia is one of the most
important factors that determine the vascular architecture of the
tumor. Particularly in the hypoxic niches of the tumor TAMs
Fig. 2. Metabolic reprogramming of TAMs shapes their functional phenotype. In response to different cues present in the TME, among which products of altered tumor cell
metabolism, TAMs undergo metabolic reprogramming, including activation of glycolysis, alterations in their TCA cycle with subsequent use of alternative metabolites (such as
glutamine) to fuel the TCA cycle, FA synthesis and altered nitrogen cycle metabolism. These changes result in functional reprogramming of TAMs which include changes in the
production of cytokines and angiogenetic factors, and contribute to the tumor growth, suppression of other immune cells and tumor progression and metastasis.
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become pro-angiogenic and pro-invasive. Wenes at al has investi-
gated recently the role of the hypoxic macrophage metabolism in
the morphogenesis of blood vessel and metastasis using a
comprehensive approach, which included gene-targeting methods,
metabolic assays, bone marrow transplantation and pharmaco-
logical interventions [54]. The study revealed that in hypoxic con-
ditions, TAMs up-regulate their REDD1 (regulated in development
and in DNA damage response 1), which inhibits mTOR, and sub-
sequently inhibited the glycolysis. This was associated with an
increased angiogenic response and formation of aberrant leaky
vessels. On the other hand, REDD1-deﬁcient TAMs are able to
outcompete the neighboring endothelial cells for glucose through
activation of mTOR and increased glycolysis, which is associated
with normalization of vascular structure, less leakage of tumor cells
into the blood vessels and less metastases [54]. This observation is
of great relevance as it does not only give mechanistic insight in the
process of angiogenesis, but can have implications for therapy as
well. Many malignant tumors are being treated with mTOR in-
hibitors and the results of Wenes et al. suggest that the favorable
effect of these medications could be hampered by their effects on
the TAMs metabolism through subsequent changes in their func-
tional phenotype.
Lipid metabolism of the TAMs
Besides glucosemetabolism, TAMs undergo also changes in lipid
metabolism including enhanced FA biosynthesis, uptake and stor-
age, which have been associated with functional reprogramming,
although the mechanisms remain largely unknown. Several studies
also indicated that TAMs show changes in the metabolism of
arachidonic acid. By RNA-expression proﬁling of macrophages of in
the TME of lung cancer in an immunocompetent orthotopic mouse
model, Pokzobutt et al. showed increased expression of multiple
genes involved in lipid metabolism and lipid signaling in distinct
populations of macrophages. In particular, increased expression of
Cox2 and an increased PGE2 production in vitro was found in
macrophages inﬁltrating tumor-bearing lungs compared with the
macrophages from naïve lungs. This suggests that upon cancer
development, not only cancer cells but also immune cells are able
to increase their prostaglandin synthesis, resulting in a cumulative
increased prostaglandin production as it has been described in lung
tumors [65]. Previously it was shown that IL-1b-induced inﬁltration
with COX2 expressing macrophages is associated with tumor
angiogenesis and tumor growth in a murine lung cancer model
[66]. Furthermore, COX2 expression was shown in TAMs from hu-
man melanoma, but not in the macrophages from normal
epidermis adjacent to the lesions. COX2 expression was induced in
macrophages upon direct co-culture with F10-M2 murine mela-
noma cells in vitro [67]. Furthermore, TAMs isolated from human
renal cell carcinoma show an increased metabolism of arachidonic
acid mediated by 15-LO2 dependent pathways. These TAMs
showed an increased activity of 15-L02, an increased secretion the
arachidonic acid metabolite, 15(S)-HETE, and have an increased
production of the immunosuppressive CCL2 and IL-10 through a
15-LO2-dependent mechanism. This suggests that changes in their
cellular lipid metabolism directly affect the function of TAM in the
TME [68].
Lipid loading of macrophages has been associated with
increased tumoricidal and inﬂammatory capacity. Schlager et al.
has shown that an increased intracellular lipid content was asso-
ciated with an increased cytotoxic activity of murine peritoneal
macrophages, particularly in those that were artiﬁcially enriched
with polyunsaturated FAs in contrast with those enriched in
cholesterol. The cytotoxic activity of the macrophages was also
dependent on the type of FA with which the cells were artiﬁcially
enriched. As such, macrophages enriched with unsaturated FA
linolenic acid (18:3), but not those enriched with the saturated FA
stearic acid (18:0), were cytotoxic against P815 tumor cells [69]. In
line with this, TAMs from a mouse mammary adenocarcinoma
model, particularly the M1-like (MHCIIþCD11cþ) population,
expressed high levels of epithelial fatty acid binding proteins (E-
FABP), an intracellular lipid chaperone, which improved their
antitumoral activity by mounting the production of IFN-b) through
up-regulation of lipid droplet formation in response to malignancy.
This promoted further recruitment of other tumoricidal immune
cells, especially NK cells, in the TME [70,71]. In human breast tu-
mors E-FABP expression was also reduced in stroma of invasive
tumors as compared to normal stroma, and E-FABP expression of
TAMs decreased in parallel with the disease progression [71].
Furthermore, stimulating macrophages with the E-FABP activator
EI-05 enhanced lipid droplet formation and IFN-b production, and
in vivo administration of the activator in amurinemammary tumor
model signiﬁcantly inhibited tumor growth [70].
In conclusion, in response to microenvironmental cues, macro-
phages can alter their lipid proﬁle and the production of lipid
products, which may contribute to the pro-tumorigenic proﬁle of
TAMs. On the other hand, especially unsaturated FAs seem to in-
crease the cytotoxic activity of TAMs. Further studies are needed to
unravel the lipid metabolism of TAMs and its related functional
consequences.
Amino acids metabolism in TAMs
Several studies report on possible implications of amino acids
metabolism for the functional reprogramming of the TAMs. How-
ever, the majority of these studies are observational and only scarce
mechanistic insight is available.
TAMs, particularly the M2-like, pro-tumorigenic TAMs show an
increased use of glutamine. This is associated with high levels of
Uridine diphosphate N-acetylglucosamine intermediates, which
are required for N-glycosylation of M2-associated receptors.
Consequently, blocking the N-glycosylation and deprivation of
glutamine impairs the M2 polarization, with concomitant down-
regulating effect on the TCA cycle [72]. Also TAMs isolated from
with glioblastomas and TAMs exposed to glioblastoma cell lines
show increased expression of genes related to glutamate transport
and metabolism, which may be of relevance because the glioblas-
toma TME contains large amounts of glutamate [73].
L-arginine metabolism has also been linked to the function of
TAMs. In macrophages, L-arginine can be used either for the NO
synthesis or through the arginase pathway. The pro-inﬂammatory
M1-like macrophages are characterized by a more pronounced
NO synthesis pathway. Arginine is converted into NO and L-citrul-
line by the inducible nitric oxide synthase (iNOS). The produced NO
subsequently suppresses OXPHOS through the inhibition of en-
zymes involved in the TCA and electron transport chain and
upregulates glycolysis [74,75]. On the other hand, M2 macrophages
are characterized by the expression of the urea cycles enzyme
arginase (ARG1), which hydrolyzes arginine to ornithine and urea
and limits arginine availability for NO synthesis [76,77]. Further-
more, the produced ornithine can be directed into downstream
pathways of polyamine and proline synthesis, which are necessary
for cell proliferation, tissue remodeling and collagen synthesis
[50,51,76].
TAMs isolated from murine mammary and human ovarian tu-
mors TAMs show low cytotoxic properties in association with a
reduced NO production and a low iNOS mRNA expression and
protein levels in mammary tumor-bearing mice [78,79].
TAMs from various murine tumor models show elevated Arg1
expression [23,80e82]. ARG1 has long been recognized as a marker
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of M2 macrophages. Nonetheless, the function of macrophage-
derived ARG1 particularly in the context of malignancy is not
well known. Both hypoxia and lactate have been shown to be able
to increase the expression of Arg1 gene [23]. In a murine model of
lung cancer, Colegio et al. showed that Arg1ﬂ/ﬂ X Lysmcre/wt mice,
whose macrophages are deﬁcient in ARG1, develop signiﬁcantly
smaller tumors than the wild-type mice [23]. Interestingly, in the
same study TAMs were showed to have increased expression of all
enzymes from the urea nitrogen cycle, which was even higher than
in the tumor cells. Furthermore, L-arginine-derived metabolites,
cysteine and tryptophan metabolism are important mediators of
the immunosuppressive activity of MDSCs [83]. These ﬁndings
suggest that urea nitrogen cycle may play an important role in the
function of TAMs, however further studies are required in order to
understand the underlying mechanisms.
Potential therapeutic implications
Therapeutic targeting of both the immune cells and the cancer
cells metabolism could have important therapeutic implications.
Several of the classical and new anti-tumoral therapeutic in-
terventions potentially induce metabolic changes in the tumor
microenvironment that can impact on the recruitment and func-
tion of the immune cells. In this respect, hypoxia-induced recruit-
ment of myeloid cells can contribute to the resistance to
conventional treatment with anti-angiogenic drugs through in-
duction of vessel formation through alternative routes [84,85].
Similarly, the acidiﬁcation of the tumor microenvironment, mainly
due to increased production of lactate, has also been found to
induce resistance to chemotherapy and immunotherapy [86].
Conversely, ketogenic diets that result in reduced lactate produc-
tion could lead to a reduced lactate-mediated immunosuppression
in the tumor microenvironment and improved anti-tumoral im-
mune responses [87,88]. Therefore, targeting the metabolic path-
ways in tumor cells and in immune cells in combination with
conventional targeted therapy could represent a novel approach to
circumvent therapy resistance and/or to synergistically enhance
the therapeutic effects. An example of such combination is repre-
sented by the treatment with anti-glycolytic agents which has been
shown to increase the cytotoxicity of sorafenib [61,63,89] in he-
patocellular carcinoma. Furthermore, mTOR inhibition has been
reported to increase the immunotherapeutic activity of a CD40
agonist in a mouse model of renal cell carcinoma [90]. On the other
hand, modulation of TAMs metabolism through REDD1-induced
mTOR inhibition and reduction of glucose uptake and glycolysis
may be another mechanism through which abnormal tumor
angiogenesis and treatment failure can occur in patients treated
withmTOR-targeting drugs [54]. Metformin, a drug widely used for
treatment of diabetes, has been shown to inﬂuence the functional
polarization of tumor-educated macrophages by inhibiting the M2-
like reprogramming [91e93], thereby suggesting that metformin
could be a potentially promising addition to the multi-targeted
armamentarium for cancer therapy. Its potential beneﬁcial effects
may also include antiproliferative effects. Furthermore, checkpoint
blockade antibodies, which are increasingly being used for treat-
ment of different cancers, have also being shown to inﬂuence the
glucose metabolism in tumors, by reducing the tumor cell glycol-
ysis and glucose consumption, thereby improving the glucose
availability required for the metabolic ﬁtness and antitumoral
function of immune cells, speciﬁcally the tumor inﬁltrating CD8þ T
lymphocytes [94].
These therapeutic implications are not limited to modulation of
glucose metabolism. Atorvastatin, a frequently prescribed HMG-
Coa reductase and cholesterol synthesis inhibitor, promotes M2-
like functional reprogramming of TAMs in a murine model of
pancreatic cancer thereby reducing the effects of the chemothera-
peutic agent gemcitabine [95]. Altogether, these ﬁndings support
the concept of metabolic interplay in the TME as a driver of cancer
progression and response to therapy.
Concluding remarks
The role of metabolic reprogramming of both the tumor cells
and the immune cells present in the TME has increasingly been
recognized as a crucial pathway contributing to the complex dialog
between these cells. However, the mechanistic insight of the mo-
lecular pathways leading to these changes is still limited. This
partially precludes at this point therapeutic interventions targeting
the metabolic pathways.
Despite these limitations, one can envisage the targeting of
cellular metabolism as a therapeutic approach in malignancies. On
the one hand, inhibition and modulation of cancer cell metabolism
is an approach that has been long sought, and it starts to bear fruits
by the use of glycolysis inhibitors such as mTOR inhibitors. On the
other hand, it can also be suggested that understanding the par-
ticularities of cellular metabolism of pro-tumorigenic TAMs would
enable additional treatments. Targeting speciﬁcally the TAMs can
be achieved by the progress in liposome and nanoparticle drug-
delivery systems. Furthermore, combined therapy between
recently discovered immunotherapeutic agents (e.g. anti-PD1/
PDL1, anti-CTLA4) and inhibitors of cellular metabolism can also
be envisaged.
To achieve however the aim of speciﬁc metabolic targeting of
immune cells in cancer, outstanding questions still need to be
addressed. Among them, several important questions are: the
speciﬁcity of cellular metabolism of macrophages in the primary
and metastatic tumors, assessment of the potential existence of
subpopulations of TAMs using single-cell technologies, identiﬁca-
tion of the main enzymatic pathways responsible for these changes
and which can be targeted. Only when the answers to these
questions will be available will we be able to fulﬁl the therapeutic
potential of targeting the cellular metabolism of immune cells in
cancer.
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